Zealand Pharma A/S represents values of innovation, collaboration, and patient-centricity. The company is focused on discovering, developing, and commercializing innovative peptide-based medicines to address unmet medical needs. With a strong commitment to scientific excellence, Zealand Pharma A/S continuously strives to improve the lives of patients by delivering transformative therapies. The company's corporate philosophy revolves around driving positive change in the healthcare industry and making a meaningful impact on individuals' well-being. Zealand Pharma A/S aims to actively engage with stakeholders, foster partnerships, and leverage its expertise to develop breakthrough treatments that address complex diseases. Through its dedication to research and patient-centric approach, Zealand Pharma A/S continues to shape the future of healthcare.

Zealand Pharma A/S is primarily present in Denmark, as it is a Danish biotechnology company.

Zealand Pharma A/S has achieved significant milestones in its journey. The company has successfully developed innovative therapies targeting metabolic and gastrointestinal diseases. Their impressive portfolio includes glepaglutide, a potential treatment for short bowel syndrome, and dasiglucagon, a potential rescue treatment for severe hypoglycemia. Zealand Pharma has also secured strategic partnerships, collaborating with leading pharmaceutical companies to further advance their research and development efforts. With a focused approach on improving patients' lives, Zealand Pharma continues to make strides in the field of biotechnology and is set to create a positive impact in the healthcare industry.

Zealand Pharma A/S is a prominent biotechnology company specializing in the development of innovative peptide-based medicines. Founded in 1998 in Denmark, Zealand Pharma has established itself as a key player in the field of therapeutic peptides. With a focus on treatments for metabolic and gastrointestinal diseases, the company has a strong track record of successful collaborations and a robust pipeline of potential therapies. Zealand Pharma's commitment to research and development, along with its driven team of experts, has allowed the company to consistently deliver groundbreaking solutions in the healthcare sector. Building on its rich history and extensive expertise, Zealand Pharma A/S continues to pave the way for advancement in peptide-based medicine.

The main competitors of Zealand Pharma A/S in the market are AstraZeneca, Novo Nordisk, and Eli Lilly.

The primary industries in which Zealand Pharma A/S is active are biotechnology and pharmaceuticals.

The business model of Zealand Pharma A/S focuses on the development and commercialization of innovative peptide-based medicines. As a biotechnology company, Zealand Pharma A/S specializes in the discovery and development of therapeutic solutions for patients suffering from metabolic and gastrointestinal diseases. They strive to address unmet medical needs by utilizing their expertise in peptide science and advancing their proprietary pipeline. Zealand Pharma A/S aims to establish strategic partnerships and collaborations while ensuring rigorous research and clinical trials to bring novel treatments to patients worldwide. Their commitment to innovation and dedication to improving healthcare contributes to the growth and success of Zealand Pharma A/S.

Коефициентът на цена спрямо печалбата (КЦП) на Zealand Pharma A/S е -61,92.

Коефициентът на цена към оборот (KUV) на Zealand Pharma A/S е 266,58.

AlleAktien качественият резултат за Zealand Pharma A/S е 4/10.

очаквана Zealand Pharma A/S оборотът е 194,34 млн. DKK.

очаквана Zealand Pharma A/S печалба е -836,65 млн. DKK.

Zealand Pharma A/S is a Danish biotechnology company specializing in the discovery, development, and distribution of innovative therapies for the treatment of metabolic and gastrointestinal diseases. The company was founded in 1998 and is headquartered in Copenhagen. The business activities of Zealand Pharma are divided into two main divisions: the research and development of new therapeutics and the marketing of products the company has already developed. In terms of research and development, the company focuses on identifying peptides and proteins that have specific interactions with metabolic receptors. This includes both specific hormones and receptors. The discovered peptides can then be used for the development of new drugs. Some of Zealand Pharma's key product candidates include the diabetes treatment drug Lyxumia, which is already approved in Europe and used as a pacemaker in heart rate regulation for patients with heart failure, as well as the diabetes drug ZP2929. The company is also developing several other potential therapeutics, including medications for the treatment of obesity and overweight. In the product pipeline division, Zealand Pharma has two commercially approved products: the dietary supplement DiaResQ and the anti-diabetes medication Soliqua. These products are marketed in the North American market. The company also has partnerships with some of the world's leading pharmaceutical companies such as Sanofi, Roche, and Boehringer Ingelheim. With these partners, the company is working on the development of new drugs for the treatment of diabetes, obesity, and other metabolic diseases. Zealand Pharma's business strategy is to drive the market launch of new therapy options based on its extensive experience in the research and development of metabolic and gastrointestinal diseases. The company aims to establish itself as a key player in the pharmaceutical and biotech industry and expand its portfolio to broaden the range of treatments. Overall, Zealand Pharma A/S is an innovative biotechnology company focused on the development and marketing of therapeutics for the treatment of metabolic and gastrointestinal diseases. The company has a broad portfolio of products and product candidates and has a strong presence in the North American market. Thanks to its partnerships with leading pharmaceutical companies, the company could play a significant role in the development of new therapy options in the future.

Zealand Pharma A/S разпределя дивидента от 0 DKK на плащания годишно.

Дивидентата за Zealand Pharma A/S в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Zealand Pharma A/S е DK0060257814.

WKN на Zealand Pharma A/S е A0YJW7.

Тикерът на Zealand Pharma A/S е ZEAL.CO.

През последните 12 месеца Zealand Pharma A/S изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Zealand Pharma A/S да изплати дивиденда в размер на 0 DKK.

Дивидентната доходност на Zealand Pharma A/S в момента е .

Zealand Pharma A/S изплаща дивидент на тримесечие. Той се разпределя в месеците .

Zealand Pharma A/S платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 DKK. Това съответства на дивидентна доходност от 0 %.

Zealand Pharma A/S се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Zealand Pharma A/S на 16.09.2024 г. в размер на 0 DKK, трябваше да притежавате акцията в портфейла си преди Ex-деня на 16.09.2024 г..

Последното дивидентно плащане беше извършено на 16.09.2024 г..

През година 2023 Zealand Pharma A/S изплати 0 DKK под формата на дивиденти.

Дивидентите от Zealand Pharma A/S се изплащат в DKK.